Ascendis Pharma A/S $ASND priced its secondary offering of 6,315,789 American Depository Shares (ADS) at $19. Each ADS equals to one ordinary share. Underwriters will have an option to purchase an additional 947,368 ADSs. The closing date of offer is October 24. The net proceeds from the offering will be about $120 million. It will be used to fund clinical development and regulatory approval of Transcon Growth Hormone, the development of other lead candidates, working capital requirement and other general corporate purposes. The stock closed at $20.09 on Tuesday.